Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43251
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHussein, H-
dc.contributor.authorZaccardi, F-
dc.contributor.authorDhalwani, N-
dc.contributor.authorDavies, M-
dc.contributor.authorKhunti, K-
dc.contributor.authorGray, L-
dc.date.accessioned2019-02-06T15:57:36Z-
dc.date.available2019-02-06T15:57:36Z-
dc.date.issued2018-11-09-
dc.identifier.citationBMJ Open, 2018; 8:e023206.en
dc.identifier.issn2044-6055-
dc.identifier.urihttps://bmjopen.bmj.com/content/8/11/e023206en
dc.identifier.urihttp://hdl.handle.net/2381/43251-
dc.description.abstractIntroduction Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are two classes of glucose-lowering drugs gaining popularity in the treatment of type 2 diabetes mellitus (T2DM). Current guidelines suggest patient-centred approaches when deciding between available hyperglycaemia drugs with no indication to which specific drug should be administered. Despite systematic reviews and meta-analyses being conducted within SGLT-2is and GLP-1RAs, differences across these classes of drugs have not been investigated. Therefore, this systematic review and network meta-analysis (NMA) will aim to compare the efficacy and safety profiles across and within SGLT-2is and GLP-1RAs. Methods PubMed, the Cochrane Central Register of Controlled Trials and ISI Web of Science will be searched from inception for published randomised controlled trials conducted in patients with T2DM, with at least two arms consisting of SGLT-2is, GLP-1RAs or control/placebo. Title and abstracts will be screened by two independent reviewers with conflicts resolved by a third. Data will be extracted by the primary researcher, a random sample will be checked by an independent reviewer. Risk of bias will be assessed using the Cochrane Risk of Bias Tool and overall quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. Study characteristics, participants baseline characteristics, mean change in cardiometabolic outcomes and number of adverse events will be extracted for each study. Primary outcome will be the mean change in glycated haemoglobin (HbA1c) (%, mmol/mol). Initial random-effects pairwise meta-analysis will be conducted for each unique treatment comparison where heterogeneity will be assessed. A Bayesian NMA approach will be adopted where random-effects generalised linear models will be fitted in WinBUGS. Sensitivity analysis will be conducted to assess choices of prior distributions and length of burn-in and sample. Ethics and dissemination Ethics approval is not required for this study. Results from this study will be published in a peer-review journal. PROSPERO registration number CRD42018091306.en
dc.description.sponsorshipThis report is the independent research of HH supported by the National Institute of Health Research Collaborations for Leadership in Applied Health Research and Care–East Midlands (NIHR CLAHRC–EM) as part of a PhD project. FZ is a Clinical Research Fellow supported by the NIHR CLAHRC–EM.en
dc.language.isoenen
dc.publisherBMJ Publishing Groupen
dc.rightsCopyright © the authors, 2018. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium non-commercially, provided the original author and source are credited.en
dc.titleEfficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocoen
dc.typeJournal Articleen
dc.identifier.doi10.1136/bmjopen-2018-023206-
dc.description.statusPeer-revieweden
dc.description.versionPublisher Versionen
dc.type.subtypeArticle-
pubs.organisational-group/Organisationen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCESen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicineen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciencesen
dc.dateaccepted2018-10-04-
Appears in Collections:Published Articles, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
Manuscript.pdfPublished (publisher PDF)249.07 kBAdobe PDFView/Open
Supplementary Material.pdfPublished (publisher PDF)93.39 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.